PROTEIN POTENTIAL LLC
Biotech · Private
Oral multivalent vaccine against enterotoxigenic E. coli, Shigella, and Salmonella Typhi using genetically engineered Ty21a vaccine strain expressing recombinant antigens
proteinpotential.com →- Grants
- $2.4M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 2 granted · 5 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Live Attenuated Oral Typhoid-Shigellosis Vaccine | $307,387 | |
| Federal grant | Department of Health and Human Services · Phase I · Live Attenuated Oral Typhoid-Shigellosis Vaccine | $609,197 | |
| Federal grant | Department of Health and Human Services · Phase I · Live Attenuated Oral Typhoid-Shigellosis Vaccine | $301,810 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers | $297,487 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers | $591,329 | |
| Federal grant | Department of Health and Human Services · Phase I · Multivalent Oral Vaccine against Enterotoxigenic Escherichia coli and Enteric Fevers | $293,842 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3047 | CASCADE THERAPEUTICS, INC. | — | — |
| 3048 | BACCHUS THERAPEUTICS INC | — | — |
| 3049 | INFINITESIMAL, LLC | — | — |
| 3050 | PROTEIN POTENTIAL LLC | — | — |
| 3051 | Alentis Therapeutics | — | — |
| 3052 | OLFA THERA, INC. | — | — |
| 3053 | Pharmareview Corporation | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Live Attenuated Oral Vaccine Against COVID-19 And Typhoid Feverapplication
- Live Attenuated Oral Vaccine Against Etec And Typhoid Fevergranted
- Live Attenuated Oral Vaccine Against Shigellosis And Typhoid Fevergranted
- Live Attenuated Oral Vaccine Against COVID-19 And Typhoid Feverapplication
- Live Attenuated Oral Vaccine Against Shigellosis And Typhoid Feverapplication
- Live Attenuated Oral Vaccine Against Shigellosis and Typhoid Feverapplication
- Dna Sequences, Peptides, Antibodies And Vaccines For Prevention And Treatment Of Sarsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.